WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical and biotechnology companies, today announced that it has signed additional new business contracts valued at approximately $2.2 million with multiple European and U.S. biopharmaceutical companies. The therapeutic areas included in these awards are oncology, pulmonary arterial hypertension, infectious diseases, immunology/vaccines, and women’s health. Services to be provided include consulting, regulatory affairs, project management, field monitoring, and medical monitoring/writing. Revenue recognition is expected to occur on a proportional performance basis as services are performed on each project.
